Les thymorégulateurs en psychiatrie de l'enfant et de l'adolescent

Translated title of the contribution: Thymoregulators in child psychiatry and adolescents

Bertrand Lauth*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The high prevalence of bipolar disorders in the United States has led to a considerable increase in prescription rates of mood stabilizers as well as atypical neuroleptics. Apart from antipsychotics, lithium is the only approved mood stabilizer both in France (after 16 years of age) and in the US (after 12 years of age). It is recommended to start with monotherapy for acute mania or mixed state. In the case of inadequate results, a mood stabilizer-antipsychotic combination may be necessary. Olanzapine-fluoxetine combination is approved for the treatment of pediatric bipolar depression. Further studies are needed to evaluate the safety and efficacy of mood stabilizers in acute and maintenance treatment of pediatric bipolar disorders, as well as in autistic spectrum and disruptive disorders.

Translated title of the contributionThymoregulators in child psychiatry and adolescents
Original languageFrench
Pages (from-to)500-505
Number of pages6
JournalInformation Psychiatrique
Issue number6
Publication statusPublished - 1 Jun 2018

Bibliographical note

Publisher Copyright:
Copyright © 2018 John Libbey Eurotext.

Other keywords

  • Adolescent
  • Bipolar disorders
  • Depression
  • Enfant
  • Mania
  • Mood stabilizers
  • Pharmacopsychologie
  • Psychopharmacology
  • Thymorégulateur
  • Trouble bipolaire


Dive into the research topics of 'Thymoregulators in child psychiatry and adolescents'. Together they form a unique fingerprint.

Cite this